AstraZeneca invests nearly $30 million to upgrade base in China

2

BEIJING, Sept 17 (Reuters) – AstraZeneca unveiled an investment of nearly 200 million yuan ($29.81 million) to upgrade its production and supply base in Wuxi, China, the company's Chinese unit said in

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)